Detrimental effect of atazanavir plasma concentrations on total serum bilirubin levels in the presence of UGT1A1 polymorphisms by P. Cicconi et al.






Wever et al1 report ‘‘incomplete
reversibility of tenofovir (TDF)-related
renal toxicity in HIV-infected men’’. The
authors’ report highlights that TDF-
related renal toxicity may not always
be fully reversible, particularly in those
with gradual decline in estimated glo-
merular filtration rate (eGFR). The study
describes 24 patients who ceased TDF
for suspected renal toxicity and com-
pared serum creatinine with eGFR
(Cockcroft-Gault and Modification of
Diet in Renal Disease) before initiating
TDF, at the time of stopping TDF, and
the most improved value after stopping
TDF. The median age of the patients was
56 years, the median duration of TDF
exposure 30 months, the median eGFR
at TDF initiation 74 mlmin11.73 m2,
and most patients received protease
inhibitors and had good virological
control. At the time of TDF discontin-
uation, the eGFR (Modification of
Diet in Renal Disease) had declined to
51, with subsequently improvement to
64 mlmin11.73 m2 (most improved
value) and 58 mlmin11.73 m2 (most
recent measurement). The authors con-
clude that TDF-associated renal toxicity
was not fully reversible in 58% of
subjects. Although this may be correct,
it should be appreciated that many
patients with reduced eGFR (<90 or
<75 mlmin11.73 m2) may have
underlying chronic kidney disease, the
natural history of which may be
progressive in nature. Consequently, over
a 3-year period (30 months of TDF
exposure and 5 months of recovery),
eGFR declines that are observed in the
setting of drug-induced renal injury may
not recover fully after drug discontinu-
ation when the underlying renal disease
has progressed during this time. This
would be more likely if drug exposure
has been prolonged and if drug-induced
kidney injury was insidious in onset. We
propose that eGFR slopes may provide
better insight into the potential revers-
ibility of TDF-associated nephrotoxicity,
as they allow estimation of the rate of
CKD progression before TDF initiation,
during TDF exposure, and after TDF
discontinuation.
We analyzed renal function using
eGFR slopes in 843 patients who initiated
TDF-containing cART, and of whom
26 (3.1%) developed CKD (defined as
an eGFR <60 mlmin11.73 m2 for
>3 months). Compared with patients
who did not develop CKD, those
who developed CKD were older (53.6
vs 39.9 years, P < 0.001) and had sig-
nificantly lower eGFR at TDF initiation
(69 vs 102 ml per minute, P < 0.001).
In addition, 85% had other risk factors
for CKD progression including underly-
ing cardiovascular disease or exposure
to other potentially nephrotoxic drugs.2
When changes in renal function over
time were examined, patients who devel-
oped CKD already experienced modest
eGFR decline (2.3 mlmin1year1)
before TDF initiation. Accelerated
decline in eGFR (median –8.5
mlmin1year1) was observed during
TDF exposure, with subsequent return to
the pre-TDF eGFR slope of –2.2
mlmin1year1 after TDF discontinua-
tion. In patients who did not develop
CKD, a similar, but much more modest
decline in eGFR was observed (Table 1).
Even though our data suggest that
TDF-related renal toxicity may be largely
reversible, it clearly is best avoided by
monitoring changes in renal function
over time. Although the optimal fre-
quency of monitoring is unknown, the
modest rate of renal disease progression
in patients on TDF would support annual
or biannual assessment of renal function.
Although we agree with Wever et al1 that
an eGFR >60 mlmin11.73 m2 may
lead to consideration of TDF discontin-
uation, it may be important to identify
those at greatest risk of TDF-associated
renal toxicity, including those aged >50
(odds ratio: 5.4) and patients who have
eGFR <75 mlmin11.73 m2 at TDF
initiation (odds ratio: 17.2),2 and either
avoid TDF if suitable alternatives are
available, or use TDF with more close
monitoring of renal function.
Lucy J. Campbell, MSc
Lisa Hamzah, MBChB
Frank A. Post, MD PhD FCP(SA)
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Initiation During TDF Use
Following TDF
Discontinuation
Patients who developed CKD 2.3 (3.2 to 1.4) 8.5 (9.4 to 7.6) 2.2 (6.6 to +2.1)
Patients without CKD +1.2 (+1.1 to +1.4) 0.8 (1.1 to +0.2) +3.9 (+2.1 to +5.1)
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tenofovir-related nephrotoxicity is
not always fully reversible. They
correctly note that we did not report
the rate of decline in estimated
glomerular filtration rate (eGFR)
before initiation of tenofovir. They
state that tenofovir-related nephro-
toxicity is reversible because the
decline in eGFR in those who devel-
oped chronic kidney disease (eGFR <60
mL min11.73 m2 for at least 3
months) was similar before tenofovir
initiation and after tenofovir cessation
(2.3 mL min11.73 m2 per year and
2.2 mL min11.73 m2 per year,
respectively).
However, the rate of change after
tenofovir discontinuation will be the
sum of the rate due to pre-existing renal
disease and of the rate of recovery from
tenofovir toxicity. If tenofovir-related
nephrotoxicity were reversible, the rate
of change after tenofovir cessation
must be less (ie, more positive) than
the rate before cessation, as the un-
derlying rate of decline associated with
pre-existing renal disease would nec-
essarily be lessened by any increase in
eGFR after tenofovir cessation. For
example, if eGFR declined by 2.3 mL
min11.73 m2 per year before tenofovir,
then declined by 8 mL min11.73 m2
per year on tenofovir and then fully
reversed, then the rate of change after
tenofovir cessation would be about
+5.73 mL min11.73 m2 per year. The
similar rates before and after tenofovir
therapy in the population described by
Campbell et al suggest that tenofovir
nephrotoxicity was, as in our patients,
also not reversible in those who developed
chronic kidney disease.
Our interpretation of these new
data is that tenofovir nephrotoxicity does
not progress when tenofovir is stopped
but that tenofovir nephrotoxicity is not
fully reversible.
Andrew Carr, MBBS, MD,
FRACP, FRCPA
HIV, Immunology and Infectious Diseases
Unit and Head,
Clinical Research Program Centre for
Applied Medical Research
St Vincent’s Hospital Professor of Medicine










Atazanavir (ATV), a protease in-
hibitor of HIV, acts as an inhibitor of the
UDP-glucuronosyltransferase (UGT)1A1,
an enzyme responsible for bilirubin me-
tabolism, leading to unconjugated hyper-
bilirubinemia.1 The frequency and the
severity of hyperbilirubinemia correlates
with the UGT1A1 gene polymorphisms,
mimicking the mechanism underlying
Gilbert Syndrome.2,3 Furthermore, biliru-
bin levels directly correlate with ATV
plasma concentrations.3,4 To our knowl-
edge, the interaction between ATV plasma
concentrations and the UGT1A1 poly-
morphism has never been formally tested,
assuming their effects to be additive. The
aim of this study is to assess whether the
impact of ATV plasma concentrations on
serum bilirubin was different according to
the presence of UGT1A1-TA7 allele.
Patients cared at our Institute
treated with ATV 300 mg plus ritonavir
100 mg (ATV/r) and 2 nucleoside
analogues for longer than 3 months were
identified. Plasma ATV concentration
was measured after 24 6 4 hours drug
intake [trough concentration (Ctrough)] by
a validated high-performance liquid
chromatography method.5 Genetic pro-
file of the UGT1A1 gene was assessed by
direct sequencing of DNA extracted from
peripheral blood mononuclear cell.6
Descriptive results of continuous
variables were expressed as median and
interquartile range (IQR) values. Univar-
iate and multivariate linear regression
models were used to investigate factors
correlated with total serum bilirubin.
Sixteen of 55 patients (29.1%) were
female, the median age was 43 years
(IQR 39–49), and the body mass index
(BMI) was 23.7 (IQR 21.8–25.5). The
CD4 cell count was 468 cells per micro-
liter (IQR 336–588). The median follow-
up on ATV was 14.5 months (IQR 5–32).
The median serum bilirubin was 2.53 mg/
dL (IQR 1.31–3.94), and the proportion of
patients with grade 3 (>2.5 3 Upper
Normal Limit [ULN]) and grade 4 (>5 3
ULN) hyperbilirubinemia was 50.1% and
12.7%, respectively. The median ATV
Ctrough was 1 mg/L (IQR 1–3). The dis-
tribution of UGT1A1 genotypes was as
follows: TA6/TA6 in 43.6%, TA7/TA6
n 40%, TA7/TA7 in 16.4%. The median
bilirubin level in each genotype was:
2.1 mg/dL (IQR 1.2–2.8) in TA6/TA6,
2.58 mg/dL (IQR 1.3–3.9) in TA6/TA7,
5.2 mg/dL (IQR 3.0–7.6) in TA7/TA7
(P = 0.05). There were no significant dif-
ferences between the 3 genotypes in terms
of age, gender, BMI, CD4 count, and
ATV plasma level. When total serum
bilirubin was regressed on ATV plasma
concentration and UGT1A1 polymor-
phism, the expected difference in total
bilirubin resulted: 1.49 (SE 0.38; P =
0.0003) per unit difference in ATV Ctrough,
and increased of 1.39 factor (SE 0.51;
P = 0.0009) if at least 1 UGT1A1-TA7
allele was present (rho2 = 0.26). To test
whether the difference in total bilirubin
per unit difference in ATV plasma con-
centrations changed according to the
presence of the UGT1A1-TA7 allele, a
polymorphism-by-ATV Ctrough interaction
term was included in the model. The
increase in total bilirubin per unit differ-
ence in ATV Ctrough resulted 0.80
(SE 0.39) in patients with TA6/TA6
genotype and 2.33 (SE 0.64) in patients
carrying at least one TA7 allele (rho
2 =
0.29; P for interaction = 0.04). The model
did not change after adjusting for age,
gender, CD4 count, and BMI. In addition,
older age resulted independently corre-
lated serum bilirubin level (Table 1).
The above results confirm a direct
correlation between ATV plasma level and
bilirubinemia that was influenced by the
presence of homozygosis or heterozygosis
for UGT1A1-TA7 allele. Other authors
concluded that severe hyperbilirubinemia
was further increased by the presence of
the UGT1A1-TA7 allele,
3 however, to the
best of our knowledge, this is the first study
that formally tested the interaction between
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Superiore di Sanità, ‘‘National research pro-
gram on AIDS,’’ Italy.
Letters to the Editor J Acquir Immune Defic Syndr  Volume 56, Number 3, March 1, 2011
e96 | www.jaids.com q 2011 Lippincott Williams & Wilkins
these 2 major predictors of hyperbilirubi-
nemia in patients treated with ATV. In
particular, carrying UGT1A1- TA7 poly-
morphism accounted for a 2-fold increase
in bilirubin level for a unit change in ATV
plasma concentration (Table 1). In keeping
with literature findings,5,7 severe hyper-
bilirubinemia and hepatic toxicity were
rare in our study population; only 2 patients
showed increased (>2.5 times ULN) liver
transaminase leading to interpret the herein
observed hyperbilirubinemia as an inno-
cent phenomenon (data not shown). In-
deed, bilirubinemia and/or transaminase
increases may not be frequently detected
in patients on stable therapy, given that
premature drug discontinuation occurs in
subjects nontolerating the compound. The
key question is: would UGT1A1 testing
be cost-effective in the presence of an
apparently innocent side effect?
The occurrence of jaundice may be
considered undesirable by some patients,
thus limiting adherence to ATV and
increasing the probability of treatment
failure. Furthermore, studies linked the
reduced glucuronidation activity in the
presence of the TA7 allele, to cancer
disposition8 and severe unwanted drug
reactions.9 ATV, acting as an inhibitor
of UGT proteins, might enhance these
effects particularly in individuals who
already suffer from reduced UGT activ-
ity. Findings that better characterize the
interaction between ATV plasma con-
centration and serum bilirubin may help
in dose adjustments under the guidance
of therapeutic drug monitoring. In gen-
eral, haplotype identification as pharma-
cogenomic risk factors might improve
drug safety and establish individualized
pharmacotherapy.
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Multiple studies have demon-
strated the relatively low clinical impact
and cost of frequent laboratory monitor-
ing of asymptomatic patients receiving
antiretroviral therapy (ART) in resource-
poor settings.1,2 We propose taking these
conclusions a step further into resource-
rich settings given the rising cost of
healthcare.
The costs for treatment and med-
ical care of an HIV-positive individual in
the United States are as high as $34,000
per year with estimated lifetime costs
surpassing 1 million dollars per patient.3
Furthermore, it is anticipated that the
number of patients on ART, the time on
therapy, and the commensurate costs will
continue to increase.4–10 Given this rising
number, it is critical that evidence based
on best practices with regard to efficacy,
safety, and cost-effectiveness is em-
ployed in the treatment of HIV. Current
HIV treatment guidelines recommend
that routine laboratory monitoring
should be conducted every 3 months to
monitor treatment effects, virologic
breakthroughs, and timely detection of
toxicities.8 However, with the advent of
newer more efficacious ARTs with re-
duced toxicities, these older recommen-
dations need to be re-evaluated.
We conducted a retrospective
cohort study of existing medical record
TABLE 1. Variation in Total Bilirubin Plasma Level Per Unit Difference in ATV Plasma
Trough Concentrations According to the Presence of the UGT1A1-TA7 Allele: Results
Form Linear Regression Models
Predictor
Unadjusted Model* Adjusted Model†
b (SE) P b (SE) P
ATV Ctruogh
TA6/TA6 +0.80 (0.39) 0.04‡ +1.02 (0.40) 0.08‡
TA7/TA6-7 +2.33 (0.64) +2.30 (0.62)
Female gender d d 0.31 (0.56) 0.58
Age (1 year older) d d +0.05 (0.02) 0.05
BMI (1 additional unit) d d 0.07 (0.05) 0.16
CD4 (every additional 100 cell/mL) d d 0.03 (0.13) 0.78
*Total serum bilirubin regressed on ATV Ctruogh ATV, UGT1A1 polymorphism and polymorphism-by-ATV Ctrough
interaction term.
†Same model as above adjusted for gender, age, BMI, and CD4 count.
‡The P value for interaction.
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data in our Southern California clinics to
evaluate differences in HIV-1 RNA levels
and CD4+ cell counts of patients seen
every 3 months as compared with those
seen every 6 months. We selected records
for inclusion in this analysis if the patient
had (1) been on antiretroviral therapy for
at least 3 months before data extraction,
(2) >95% adherence to ARTs, and (3)
had routine CD4+ cell counts and HIV-1
RNA levels checked either at 3-month or
at 6-month intervals. We selected pa-
tients with high adherence to limit
potential confounding effects of adher-
ence on the biomarkers of interest.
Between September 1, 2008, and
September 1, 2009, a total of 846 eligible
patients were identified and included
in our analysis. We found no differences
in terms of gender, race/ethnicity, base-
line CD4+ cell counts, and HIV-RNA
levels between those who were seen at
regularly scheduled 3-month follow-up
visits as compared with those who had
a 6-month follow-up visit (Table 1). No
differences were noted in HIV-1 RNA
levels at follow-up (P value = 0.65),
however, clinically minimal though sta-
tistically significant improvements were
noted in CD4+ cell counts (29 cells/uL
vs. 6 cells/uL; P = 0.03).
One of the critical questions regard-
ing antiretroviral therapy management is
what constitutes optimal monitoring, and
clearly this issue has implications for
resources allocation. Evidence should
guide policies for laboratory monitoring,
especially if data shows that this may not
be a good use of resources. Nationally,
there is a need for a randomized pro-
spective study evaluating the safety of
limited laboratory monitoring in stable
patients on ART to demonstrate if this is
a good use of resources in a time of
dwindling health care dollars.
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Probiotics: The





After early microbicide candidates
failed in clinical trials to prevent HIV,
TABLE 1. Demographic and Clinical Characteristics of Patients Seen Quarterly as
Compared With Patients Seen Semiannually, AIDS Healthcare Foundation, Los
Angeles, CA, September 1, 2008, to September 1, 2009
Quarterly
Testing (n = 513)
Semiannual
Testing (n = 333) P
Age, mean (SD) 45.9 (9.7) 44.3 (9.1) <.01
Gender, n (%)
Male 433 (84.4) 304 (91.3) 0.16
Female 65 (12.7) 25 (7.5)
Transgender 15 (2.9) 4 (1.2)
Race/ethnicity, n (%)
African American 73 (14.2) 74 (22.2) 0.44
Asian 16 (3.1) 11 (3.3)
Hispanic 266 (51.8) 143 (42.9)
White 154 (30.0) 104 (31.2)
Other 4 (0.8) 1 (0.3)
CD4+ cells/ul, mean (SD)
Initial test 578 (285) 555 (266) 0.21
Follow-up test at 6-months 607 (290) 561 (266) d
Difference (Follow-up test - Initial test) 29 (6.4) 6 (8.2) 0.03
P value for difference* <0.01 0.47 d
HIV-1 RNA levels (log10 copies/ml), mean (SD)
Initial test 1.84 (0.6) 2.11 (0.9) 0.10
Follow-up test at 6 months 1.82 (0.5) 2.07 (0.5) d
Difference (Follow-up test - Initial test) 0.02 (0.5) 0.04 (0.8) 0.65
P value for difference* 0.31 0.34 d
*The P value based on a t test.
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recent news from the South African
CAPRISA-004 study suggest that the
new generation of vaginal microbicide
gels using antiretroviral drugs like teno-
fovir could be effective and reduce HIV
and herpes simplex virus-2 acquisition.1
This landmark study greatly energized
the field and revived enthusiasm for
the development of female-controlled
products to prevent HIV acquisition in
women, and if ongoing trials confirm the
CAPRISA-004, results lead to a licensed
product by 2014.2,3
Although the field is getting closer
to identifying an effective compound
against vaginal HIV transmission, sig-
nificant challenges remain, such as a sus-
tained coitally independent release of an
effective drug and a product formulation
and administration that suits life circum-
stances of women in developing coun-
tries. Stigma continues to limit women’s
access to HIV prevention strategies, and
many women underestimate their own
risk of HIV infection.4 Thus, a micro-
bicide product perceived to improve
overall vaginal health may decrease
possible acceptability barriers that
a single purpose product associated with
HIV prevention may face.
In late May, the biannual global
conference Microbicides 2010 held in
Pittsburgh, PA, was attended by 1000
scientists and advocates, including more
than 300 from Africa. The UCSF Bixby
Center for Global Reproductive Health
and the Consortium to Advance Multi-
purpose Innovations organized a Satellite
Symposium titled ‘‘Probiotics: the
Potential for a Live Microbicide’’. The
event provided a platform for researchers
working in related fields to educate the
conference audience and to initiate a dis-
cussion with other scientists, donors,
advocates, members of federal agencies
and world bodies, and regulatory experts
to accelerate the development of pro-
biotics for HIV prevention.
A handful of small biotechnology
companies and academic groups are work-
ing to develop a new generation of
genetically enhanced probiotics by insert-
ing genes which code for potent antiviral
compounds into bacteria that naturally
colonize the vagina. Once administered
to the vagina, these next generation pro-
biotics have the potential to serve as a
sustained, self-replicating delivery system
for antimicrobial compounds to combat
reproductive tract infections, including
HIV. The potential advantages of a probiotic
microbicide continuously producing anti-
HIV protein compounds in situ over
conventional microbicide delivery systems
such as gels and films include (1) periodic,
possibly weekly or monthly replenishment
versus coitally dependent or daily dosing;
(2) minimal disposal concerns, for example
applicators; and (3) low risk of developing
HIV resistance in comparison to antiretro-
viral therapy commonly used in treatment,
such as tenofovir.
However, the field to date has been
hampered by a relative lack of interest
among donors due to competing HIV
prevention technologies under develop-
ment, lack of clarity regarding the
regulatory pathway for licensure and
general sensitivity surrounding geneti-
cally modified organisms (GMO), and




The normal vaginal environment is
dominated by self-replicating lactobacilli
species that maintain an acidic pH and
inhibit the growth of pathogens and
subsequent infections. Research of pro-
biotic lactobacilli to improve genital health
has increased steadily over the last 2
decades. The first generation of probiotics
uses selected human strains for the pre-
vention of recurrent bacterial vaginosis
(BV) and urinary tract infection (UTI)
following standard antibiotic treatment.
Over time, researchers in this field have
utilized new diagnostic technology such as
rDNA polymerase chain reaction and
improved product formulations and dosing
regimens. Clinical trials have successfully
demonstrated vaginal colonization with
exogenous Lactobacillus strains and pro-
vided data on effectiveness against re-
current BV5–8 and UTI.9 Advances of
these products will likely require testing of
additional approaches, such as
extending antibiotic treatment to more
effectively destroy the bacterial biofilm
and overcoming the negative influence of
semen exposure10 and menstruation on the
proportion of women colonized with the
exogenous Lactobacillus strains.
The next generation of probiotics
will be genetically engineered. Highly
potent HIV inhibitors can be
continuously produced by genetically
enhanced self-renewing Lactobacillus
bacteria that colonize the vaginal mucosa
after periodical vaginal application.
The genetically modified Lactoba-
cillus jensenii 1153-1666 (MucoCept)
developed by Osel, Inc. follows this
approach. Naturally occurring vaginal
Lactobacillus strains were evaluated, and
the L. jensenii 1153 was selected as the
single best strain. Next, this strain was
engineered to produce the potent HIV
entry inhibitor Cyanovirin-N (CV-N).
Last, Osel developed technology to pre-
serve large quantities of MucoCept as
a freeze-dried stable powder of pharma-
ceutical grade quality.
The further development of next
generation probiotics will require exten-
sive preclinical and early clinical testing
before their efficacy can be tested. To be
effective, these bacteria need to colonize
the vagina in high concentrations in
a large majority of women. In addition,
the in situ protein expression and bio-
activity and the immunological respon-
ses of the host need to be carefully
monitored. Experiments in 20 Chinese
rhesus macaques showed consistent lac-
tobacilli colonization of CV-N-express-
ing L. jensenii for up to 90 days, at high
levels of 105–107 colony-forming units
(CFU) per swab.
In theory, because the CV-N pro-
tein is ‘‘foreign’’, and the L. jensenii is
not native to the macaque, an antibody
response to either the CV-N or to the
lactobacilli is possible, rendering the
molecule inactive as a microbicide. Dur-
ing regular tests, using enzyme-linked
immunosorbent assay in macaques ex-
posed for more than 6 months, no
antibody response to either the recombi-
nant CV-N or to L. jensenii has been
found in blood or cervicovaginal lavage
samples (Dr. Qiang Xu, PhD, personal
communication, 2010). Furthermore, the
strain was easily cleared by topical
administration of azithromycin.
In a repeated low-dose challenge
model, Chinese rhesus macaques receiving
MucoCept in comparison to controls had
a 62% reduction in the rate of simian HIV
acquisition (P = 0.037) (Dr. Laurel Lage-
naur, PhD, personal communication,
2010). Next steps for the development of
this product include a prephase 1 clinical
trial of MucoCept to evaluate colonization,
clearance after antibiotic treatment and
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biocontainment in a small group of healthy
volunteers. In addition, Osel is exploring
MucoCept as a platform to coexpress
additional HIV inhibitors for as a multipur-
pose microbicide against HIV and other
sexually transmitted infections (STIs).
Other groups of researchers are
exploring similar concepts. ActoGenix,
a Belgian company, is using genetically
modified Lactococcus lactis, derived from
the food industry, as a platform to deliver
proteins such as the antiinflammatory
cytokine Interleukin-10 to downregulate
inflammatory bowel disease and ulcera-
tive colitis. A L. lactis–producing Trefoil
Factor 1 has been designed to prevent
colitis11 and oral mucositis,12 a debilitating
and painful side effect of radiotherapy and
chemotherapy. Clinical phase 2 studies
are under way for these products, and
ActoGenix is also exploring L. lactis as
a safe platform to deliver proinsulin to
treat juvenile diabetes.
Due to the mixed perception and
consideration of testing GMO in differ-
ent regions of the world and to increase
donor support to develop these products,
the field needs to educate key stake-
holders including the regulatory agencies
around the world. The regulatory ap-
proval process for probiotic drugs faces
unique challenges. First, in contrast to
probiotic foods, pharmaceutical grade
drugs need to be produced in facilities
complying with Good Manufacturing
Practices. Second, drugs that are de-
liberately releasing GMO need to follow
country-specific guidelines addressing
biocontainment and eradication. Third,
regulatory agencies in different countries
may have unique requirements that need
to be sufficiently and proactively ad-
dressed when planning for and designing
future clinical studies.
Although women in sub-Saharan
Africa have the highest need for female-
controlled HIV prevention technologies,
women in other regions also require better
prevention tools against HIV and other
STIs. In tandem with the scientific de-
velopment of these drugs, scientists and
companies should concern themselves
with the different contexts in which this
technology may be introduced. End-user
communities need to be involved from the
beginning to create awareness and ensure
their support and input for the clinical
research and the eventual marketing and
distribution. In addition to potential users,
other gate keepers like their male
partners, community leaders, and health
care providers need to be engaged.
Importantly, the daily realities of end-
users such as storage, sanitary require-
ments, disposal options, and cost need to
be considered to ensure that probiotic
microbicides proven effective for HIV
prevention will be used.
CONCLUSIONS
The CAPRISA-004 results restored
enthusiasm for microbicides as a key
technology to prevent HIV. To fulfill the
promise of microbicides, research for
additional antiretroviral compounds and
delivery mechanisms needs to be stepped
up. Women are waiting for safe, easy to
use, inexpensive, and efficacious technol-
ogies to help them prevent HIV and other
STIs. Probiotics, as a potential live micro-
bicide, offer significant advantages includ-
ing their safety profile, and a simplified
self-replicating drug delivery platform. In
addition, probiotics could serve as a com-
ponent of multipurpose prevention tools
for sexual and reproductive health to
prevent multiple adverse health outcomes
simultaneously, including HIV, STIs, un-
planned pregnancy, and other reproductive
tract infections such as BV.
As a new technology, the develop-
ment of enhanced probiotics as HIV
prevention drugs faces complex and
unique challenges including competition
for financial support, regulatory hurdles,
manufacturing and logistical barriers,
and effective branding and commercial-
ization. To overcome these barriers, it is
critical to forge multidisciplinary alli-
ances of scientists, advocates, funders,
government agencies, regulators, health
care providers, and community of end-
users. We will need to build strong
alliances to create the momentum to
successfully move live microbicides
from the laboratory to the community.
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on the Treatment as
Prevention Debate
To the Editors:
Wang et al1 provide retrospective
data regarding highly active antiretroviral
therapy coverage, HIV incidence, and
behavioral, clinical, and quality-of-life
risk factors for HIV transmission among
serodiscordant couples from Henan
Province, China.1 The study found that
HIV seroconversion rates were generally
low over time. HIV seroconversion was
associated with not always using con-
doms, having sexual activity 4 or more
times per month, not switching antire-
troviral treatment regimens, and having
a high quality-of-life score on the
psychological domain. Use of antiretro-
viral therapy by the seropositive member
of the couple was not found to be
protective against HIV seroconversion.
Although these findings are reaf-
firming of how psychological and sexual
behaviours are implicated in seroconver-
sion, they do not add meaningfully to the
discussion regarding the role of antire-
troviral treatment as prevention. We are
surprised that this is not highlighted in
the accompanying editorial.2 Quite sim-
ply, and as acknowledged by Wang et al,1
HIV transmission is directly associated
with the level of virus present in the HIV-
positive partner,3 and they are unable to
assess this relationship in this analysis, as
they do not have data on longitudinal
plasma HIV-1 virel load. As they note in
the discussion, they do not even have
data on adherence levels among those on
therapy. Furthermore, the relationship
described in this study between serocon-
version and not switching antiretroviral
treatment suggests that virological failure
may indeed be playing an important role
as a driver of HIV transmission. Com-
plete monitoring of relevant variables,
most critically plasma viral load, is
essential to address the relationship
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Antiretroviral therapy (ART) cer-
tainly has the potential to reduce HIV
transmission, and the use of treatment
as prevention is highly desirable.1 But
the magnitude and durabilty of benefit
of ART for prevention are unknown,
and the provocative observational2
and ecological studies3,4 cited in Dr
Montaner’s and Hogg’s correspondence
do not offer such insight. We need to
address 2 crucial issues as follows: (1)
How should we advise HIV discordant
couples about their transmission risk
when the infected partner is receiving
ART? (2) How do we develop a ‘‘test
and treat’’ strategy" that reliably re-
duces incident cases of HIV.
Dr Wang Lu’s article5 is important
because it reflects on both of the above
questions in the real world, not as the
result of a controlled study or a modeling
exercise. Her detection of HIV trans-
mission from people provided ART does
not negate the idea that lowering the viral
load could reduce the per-contact proba-
bility of an HIV transmission event6; this
is not an idea in dispute. But in the real
worlddfor many reasonsdpeople do not
always experience continued and reliable
suppression of HIV with ART (even in
China where treatment and care are free).
In the real world, people cannot monitor
their viral load and STDs before sexual
encounters; and suppression of HIV in
blood frequently fails to prevent HIV repli-
cation and shedding in the genital tract.7
The success of the ‘‘test and treat
strategy’’ requires that ART provided under
real-world conditionsdlike in rural China
or rural Africadreliably and durably pre-
vent transmission of HIV with reduction in
new cases of HIV; Dr Wang Lu report
highlights the obvious challenges we face
as we try to harness ART as an HIV
prevention modality.
Myron S. Cohen, MD
Institute of Global Health and Infectious
Diseases The University of
North Carolina at Chapel Hill
Chapel Hill, NC
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We read with interest the recent
article ‘‘Trends in Retention on Antire-
troviral Therapy in National Programs in
Low-Income and Middle-Income Coun-
tries’’.1 We agree that there is an urgent
need for accurate data on the outcomes of
patients on treatment, particularly as large
antiretroviral therapy (ART) programs
continue to scale-up services. As noted in
the article, South Africadwith the highest
number of people living with HIV and the
largest ART program worldwide2ddid not
report on program retention.
We have recently published a study
on the outcomes of 44,177 adults in
South Africa, approximately 10% of all
those starting public sector ART nation-
ally between 2002 and 2007.3 Based on
routinely collected data, the study pro-
vides insight into the effectiveness of
a large national ART program and has
implications for other low-income and
middle-income countries working toward
universal ART access.
We found evidence of the rapid
massive scale-up of ART: enrollment
increased 12-fold over 5 years, and 63%
of all patients were enrolled in 2006/2007.
There were strong temporal trends in
patient retention. Attrition was highest in
the first year on ART but continued with
duration on treatment: overall retention at
12, 24, and 36 months was 80%, 71%, and
64%, respectively. Over time, patient
attrition was increasingly due to loss-to-
follow-up (LTFU) compared with mortal-
ity, suggesting that there may be different
risk factors for early and late attrition on
ART. With each successive calendar year
of enrolment, too, there was an increasing
risk of appearing LTFU. For example, the
risk of appearing LTFU at 12 months on
ART was 12 times higher among patients
enrolled in 2007 than those enrolled in
2002/2003 (adjusted hazard ratio: 11.9,
95% confidence interval: 6.4 to 22).
At a program level, it is important
to characterize the patients defined as
LTFU. Some will have been misclassified
LTFU, either because they are dead4 or
because they have interrupted treatment
temporarily5; some patients recorded as
LTFU will have been lost to care, having
stopped treatment altogether, whereas
another group will be alive and in care
but considered LTFU because of admin-
istrative error including unrecorded visits
and transfers. True retention in care may
thus be underestimated.
By the end of 2009, South Africa
had initiated nearly 1 million individuals
on ART.2 The growing challenge for South
Africa and other countries with large long-
term ART programs is to find better ways
of following and retaining as many of these
patients as possible in life-long care.
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The study from Cornell et al on
a sample of approximately 10% of
patients started on antiretroviral therapy
(ART) in the public sector in South
Africa showed an increasing proportion
of patients lost to follow-up (LFU)
among patients starting in most recent
years.1 These results are of major public
health importance considering the risk of
HIV drug resistance.2 We agree with the
authors that monitoring the retention on
ART is complex and interpreting data
needs to consider potential bias in
classifying patients LFU.
Each year, the World Heath Orga-
nization and partners are collecting
national programs data including reten-
tion on ART.3 In 2009, the number of
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countries reporting and the number of
patients assessed almost doubled com-
pared with 2008.3 Among sub-Saharan
Africa countries, average retention at 12,
24, and 36 months was 74.5%, 71.9%,
and 70.4%, respectively, which is within
similar range of the 2008 results.4
Because 2009 data included part of data
reported in 2008, a trend analysis is not
possible. We observed a large variation
between countries; retention at 12 months
ranged between 47% and 96%. Such
differences cannot be attributed only to
program performance, but also reflect the
capacity of patient monitoring systems.
First, retention is overestimated when
calculated exclusively on survival with-
out taking into account patients’ LFU
and those interrupting treatment. Second,
improper recordkeeping of patients
transferred from one health facility to
another to continue treatment may result
in misclassification as LFU, hence under-
estimating retention. This bias, discussed
by Cornell et al, may increase with time
as a result of more facilities offering ART
resulting in more opportunities for
patients to be transferred. In addition,
country data may not be representative of
the full program when produced from
nonrandomly selected sites.
In 2009, a review of national
monitoring systems conducted in 13
countries in southern and eastern Africa
revealed significant variations among
countries and health facilities to effec-
tively monitor the outcomes of people on
ART. All countries had multiple paper-
based and electronic systems that were
not interoperable. Data from facilities
within the countries have different levels
of quality, hence affecting their accuracy
and representativeness at the national
level. Only seven countries had data quality
assessments conducted in the past 5 years
(Dick Chamla, personal communication).
To document program perfor-
mance, retention on ART should be
produced for each cohort of patients
starting in a specific year and also for
longer follow-up to assess the long-term
retention on ART; in 2009, at a global
level, 81% of national ART programs
were established for more than 5 years.3
Although accurate data are as critical for
patient management than for monitoring
programs, open lifelong cohort monitor-
ing for HIV care and ART presents with
unprecedented challenges as a result of
the growing number of patients and
increasing follow-up. We share our
colleagues’ concern of achieving an
accurate, simple, and sustainable moni-
toring system of patients in HIV care and
ART, ascertaining outcomes in patients
classified as LFU.5
Jean-Michel Tassie, MD, MPH*
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ERRATUM
Kaposi Sarcoma-Associated Herpesvirus Serum DNA and Antibodies Not Associated With Subsequent Non-Hodgkin
Lymphoma Risk: Erratum
The article by Beachler et al, appearing in the Journal of Acquired Immune Deficiency Syndromes, Vol 56, No. 2, pp. 188–192
entitled ‘‘Kaposi Sarcoma-Associated Herpesvirus Serum DNA and Antibodies Not Associated With Subsequent
Non-Hodgkin Lymphoma Risk,’’ an author’s name was printed incorrectly. ‘‘Charles C. Rabkin’’ should actually be listed as
‘‘Charles S. Rabkin.’’
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